Healthcare entity
AMT-130 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 132-day window averages about 0.1 stories each week. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
AMT-130 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The 132-day window averages about 0.1 stories each week. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window. The 7 average consequence score is above the beat benchmark of 6.1 in the same window. The clearest coverage concentration is market-trends: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Healthcare stories that mention Matt Kapusta, published between March 3, 2026 and July 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 643 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Matt Kapusta. Shared-story counts are live from our verified record — not editorial picks.
Type B FDA Meeting Target
Planned follow-up to define Phase III and regulatory path for AMT-130.
AMT-260 Data Readout
Expected clinical data from Phase I/IIa epilepsy study in H1 2026.
Type A FDA Meeting
Discussed AMT-130 approval pathway; alignment not yet reached.
Fiscal Year End
Closed 2025 with $622.5 million in liquidity.
The FDA’s decision to accept existing AMT-130 clinical data for a BLA submission could fast-track the first disease-modifying treatment for Huntington’s disease, with major implications for healthcare systems, payers, and patients.
Source: insidermonkey.com · finance.yahoo.com
uniQure reported a strong cash position of $622.5 million, extending its operational runway into 2029. While the company continues to seek regulatory alignment with the FDA for its Huntington’s disease candidate AMT-130, it is advancing clinical trials for epilepsy and Fabry disease with key data readouts expected in 2026.
Source: Benzinga · Globenewswire_fr
Matt Kapusta is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
